Abstract: In some embodiments, data from multiple vehicle-based natural gas leak detection survey runs are used by computer-implemented machine learning systems to generate a list of natural gas leaks ranked by hazard level. A risk model embodies training data having known hazard levels, and is used to classify newly-discovered leaks. Hazard levels may be expressed by continuous variables, and/or probabilities that a given leak fits within a predefined category of hazard (e.g. Grades 1-3). Each leak is represented by a cluster of leak indications (peaks) originating from a common leak source. Hazard-predictive features may include maximum, minimum, mean, and/or median CH4/amplitude of aggregated leak indications; estimated leak flow rate, determined from an average of leak indications in a cluster; likelihood of leak being natural gas based on other indicator data (e.g. ethane concentration); probability the leak was detected on a given pass; and estimated distance to leak source.

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.

Abstract: Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-?.

Abstract: The present invention provides fused bicyclic triazole derivatives of Formula (I) useful as gamma secretase modulators (GSM), for the treatment of Alzheimer's disease and related diseases.

Abstract: The present invention provides fused bicyclic triazole derivatives of Formula (I) useful as gamma secretase modulators (GSM), for the treatment of Alzheimer's disease and related diseases.

Abstract: A driveline assembly includes a shaft that is rotatably supported on a bearing assembly within a drive axle. The shaft has a first mount portion with a threaded exterior surface and a second mount portion with a splined exterior surface. A retaining ring is threaded onto the first mount portion to engage and retain the bearing assembly at a proper location. A yoke member with a splined inner bored is mounted on the shaft in engagement with the splined exterior surface. The yoke member can easily be connected and disconnected from the shaft without having to remove the retaining ring. The yoke member also includes a quick disconnect device that simplifies removal and re-assembly of the yoke member from the shaft.

Abstract: A driveline assembly includes a shaft that is rotatably supported on a bearing assembly within a drive axle. The shaft has a first mount portion with a threaded exterior surface and a second mount portion with a splined exterior surface. A retaining ring is threaded onto the first mount portion to engage and retain the bearing assembly at a proper location. A yoke member with a splined inner bored is mounted on the shaft in engagement with the splined exterior surface. The yoke member can easily be connected and disconnected from the shaft without having to remove the retaining ring. The yoke member also includes a quick disconnect device that simplifies removal and re-assembly of the yoke member from the shaft.